Home / Stocks / ARGX

argenx SE (ARGX, Biotechnology) Stock Valuation & Fair Value Fairly valued

argenx SE (ARGX, Biotechnology) trades at a blended P/E of 38.0, about 17% below its historical normal valuation, with a forward growth estimate of 30.9% and a PEG of 1.23. Analysts' one-year estimates have been hit 10% of the time.

No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.

DATA AS OF 2026-09-21
Blended P/E
38.0
Normal P/E
45.5
PEG
1.23
Fwd growth
30.9%
Div yield
0.0%
RSI (14)
41.0
Neutral
Technical context
  • Price $945.82 at the 2026-09-23 close, 6.4% below the 20-day average ($1,010.19) and 0.3% above the 50-day ($942.63).
  • RSI (14) at 41.0.
  • 52-week range $663.93 to $1,058.90: the price is 10.7% below the high and 42.5% above the low.

The Street vs SeerForecast

Wall Street's mean price target for ARGX is $1,180.61 across 23 analysts, 24.8% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-09-19.

Blended P/E and rating by weekBlended P/E moved from 38.0 to 38.0 between 2026-09-19 and 2026-09-21, against a normal P/E of 45.5, with 0 rating changes over 2 recorded weeks.2026-09-19: P/E 38.0, Fairly valued (recalculated)2026-09-21: P/E 38.0, Fairly valued38.040.042.044.0Sep 19Sep 20Sep 21Normal P/E 45.5
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-19P/E 38.0-17%Fairly valued
2026-09-21P/E 38.0-17%Fairly valued ← now

Frequently asked questions

Is argenx SE stock overvalued?

At a blended P/E of 38.0 versus its historical normal P/E of 45.5, argenx SE trades about 17% below its typical valuation, with a PEG of 1.23 on 30.9% forward growth. tickerseer currently rates it fairly valued.

What is argenx SE's fair value and PEG?

argenx SE trades at a blended P/E of 38.0 against a historical normal P/E of 45.5, a PEG of 1.23, and a forward growth estimate of 30.9%.

Has tickerseer's rating of argenx SE changed?

tickerseer's rating has been fairly valued since 2026-09-19.

What is the analyst price target for argenx SE?

The mean Wall Street price target for argenx SE is $1,180.61 across 23 analysts, 24.8% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ARGX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.